Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 6,556 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison C. Hoffman sold 6,556 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $180,158.88. Following the transaction, the general counsel now directly owns 152,361 shares of the company's stock, valued at $4,186,880.28. This represents a 4.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Phreesia Stock Down 1.8 %

Shares of Phreesia stock traded down $0.53 during trading on Friday, hitting $28.47. 306,682 shares of the stock traded hands, compared to its average volume of 388,179. The stock has a market cap of $1.65 billion, a P/E ratio of -19.37 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.90. The company has a fifty day moving average price of $24.98 and a two-hundred day moving average price of $23.28.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm's revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.58) EPS. Equities research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

PHR has been the topic of a number of analyst reports. JMP Securities reissued a "market outperform" rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. KeyCorp lifted their price target on Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 8th. Piper Sandler reissued an "overweight" rating and issued a $33.00 price target (up previously from $31.00) on shares of Phreesia in a research note on Wednesday. Needham & Company LLC restated a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research report on Friday, January 10th. Finally, Citigroup raised their price objective on Phreesia from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.15.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Trust Point Inc. lifted its holdings in Phreesia by 3.5% in the 3rd quarter. Trust Point Inc. now owns 17,887 shares of the company's stock worth $408,000 after purchasing an additional 607 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Phreesia by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock worth $637,000 after purchasing an additional 905 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock worth $701,000 after purchasing an additional 1,120 shares during the last quarter. R Squared Ltd acquired a new stake in Phreesia in the 4th quarter worth approximately $30,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Phreesia by 9.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company's stock worth $319,000 after buying an additional 1,258 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.